drugset / Trial / NCT07433621

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

NCT07433621

Phase 1 Recruiting 12 enrolled Children's Hospital Medical Center, Cincinnati
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.

Timeline

Start
2026-02-26
Primary completion
2028-11
Completion
2029-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Quercetin Small molecule 4000 mg Oral